世界のα1アンチトリプシン欠乏症増強療法市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-3783
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、97ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、α1アンチトリプシン欠乏症増強療法の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（グラシア、アララストNP、プロラスチンC、その他）、用途別市場規模（病院、専門診療所）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・α1アンチトリプシン欠乏症増強療法の市場動向
・企業の競争状況、市場シェア
・α1アンチトリプシン欠乏症増強療法の種類別市場規模と予測2016-2027（グラシア、アララストNP、プロラスチンC、その他）
・α1アンチトリプシン欠乏症増強療法の用途別市場規模と予測2016-2027（病院、専門診療所）
・α1アンチトリプシン欠乏症増強療法の北米市場規模2016-2027（アメリカ、カナダ）
・α1アンチトリプシン欠乏症増強療法の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・α1アンチトリプシン欠乏症増強療法のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・α1アンチトリプシン欠乏症増強療法の中南米市場規模2016-2027（メキシコ、ブラジル）
・α1アンチトリプシン欠乏症増強療法の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Grifols、CSL、Baxter、Kamada、Takeda、Abeona）
・結論

Alpha-1 antitrypsin deficiency (AATD) is an inherited condition characterized as a low or unpredictable level of alpha-1 protein, generated by liver. The disease most commonly affects lungs and liver and is often undiagnosed. Augmentation therapy is the most specific therapy for the treatment of AATD, and includes various preparations derived from pooled human plasma.

Market Analysis and Insights: Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
The global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market.

Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Scope and Market Size
Alpha-1 Antitrypsin Deficiency Augmentation Therapy market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Glassia
Aralast NP
Prolastin C
Others

Segment by Application
Hospitals
Specialty Clinics

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Grifols
CSL
Baxter
Kamada
Takeda
Abeona

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Glassia
1.2.3 Aralast NP
1.2.4 Prolastin C
1.2.5 Others
1.3 Market by Application
1.3.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Perspective (2016-2027)
2.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Trends by Regions
2.2.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Historic Market Share by Regions (2016-2021)
2.2.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Regions (2022-2027)
2.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry Dynamic
2.3.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Trends
2.3.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Drivers
2.3.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Challenges
2.3.4 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Revenue
3.1.1 Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Revenue (2016-2021)
3.1.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Players (2016-2021)
3.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue
3.4 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Concentration Ratio
3.4.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in 2020
3.5 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Players Head office and Area Served
3.6 Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Solution and Service
3.7 Date of Enter into Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Breakdown Data by Type
4.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Historic Market Size by Type (2016-2021)
4.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Type (2022-2027)

5 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Breakdown Data by Application
5.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Historic Market Size by Application (2016-2021)
5.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2016-2027)
6.2 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type
6.2.1 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021)
6.2.2 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027)
6.2.3 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2027)
6.3 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application
6.3.1 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021)
6.3.2 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027)
6.3.3 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2027)
6.4 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country
6.4.1 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2016-2021)
6.4.2 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2016-2027)
7.2 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type
7.2.1 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021)
7.2.2 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027)
7.2.3 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2027)
7.3 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application
7.3.1 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021)
7.3.2 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027)
7.3.3 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2027)
7.4 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country
7.4.1 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2016-2021)
7.4.2 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2016-2027)
8.2 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type
8.2.1 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2027)
8.3 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application
8.3.1 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2027)
8.4 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region
8.4.1 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2016-2027)
9.2 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type
9.2.1 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021)
9.2.2 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027)
9.2.3 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2027)
9.3 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application
9.3.1 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021)
9.3.2 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027)
9.3.3 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2027)
9.4 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country
9.4.1 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2016-2021)
9.4.2 Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2016-2027)
10.2 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type
10.2.1 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2027)
10.3 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application
10.3.1 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2027)
10.4 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country
10.4.1 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Grifols
11.1.1 Grifols Company Details
11.1.2 Grifols Business Overview
11.1.3 Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
11.1.4 Grifols Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
11.1.5 Grifols Recent Development
11.2 CSL
11.2.1 CSL Company Details
11.2.2 CSL Business Overview
11.2.3 CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
11.2.4 CSL Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
11.2.5 CSL Recent Development
11.3 Baxter
11.3.1 Baxter Company Details
11.3.2 Baxter Business Overview
11.3.3 Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
11.3.4 Baxter Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
11.3.5 Baxter Recent Development
11.4 Kamada
11.4.1 Kamada Company Details
11.4.2 Kamada Business Overview
11.4.3 Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
11.4.4 Kamada Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
11.4.5 Kamada Recent Development
11.5 Takeda
11.5.1 Takeda Company Details
11.5.2 Takeda Business Overview
11.5.3 Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
11.5.4 Takeda Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
11.5.5 Takeda Recent Development
11.6 Abeona
11.6.1 Abeona Company Details
11.6.2 Abeona Business Overview
11.6.3 Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
11.6.4 Abeona Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
11.6.5 Abeona Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Glassia
Table 3. Key Players of Aralast NP
Table 4. Key Players of Prolastin C
Table 5. Key Players of Others
Table 6. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions (2016-2021)
Table 10. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions (2022-2027)
Table 12. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Trends
Table 13. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Drivers
Table 14. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Challenges
Table 15. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Restraints
Table 16. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Players (2016-2021)
Table 18. Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy as of 2020)
Table 19. Ranking of Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Solution and Service
Table 23. Date of Enter into Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Type (2016-2021)
Table 27. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Application (2016-2021)
Table 31. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Country (2022-2027) & (US$ Million)
Table 63. Grifols Company Details
Table 64. Grifols Business Overview
Table 65. Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product
Table 66. Grifols Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021) & (US$ Million)
Table 67. Grifols Recent Development
Table 68. CSL Company Details
Table 69. CSL Business Overview
Table 70. CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product
Table 71. CSL Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021) & (US$ Million)
Table 72. CSL Recent Development
Table 73. Baxter Company Details
Table 74. Baxter Business Overview
Table 75. Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product
Table 76. Baxter Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021) & (US$ Million)
Table 77. Baxter Recent Development
Table 78. Kamada Company Details
Table 79. Kamada Business Overview
Table 80. Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product
Table 81. Kamada Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021) & (US$ Million)
Table 82. Kamada Recent Development
Table 83. Takeda Company Details
Table 84. Takeda Business Overview
Table 85. Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product
Table 86. Takeda Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021) & (US$ Million)
Table 87. Takeda Recent Development
Table 88. Abeona Company Details
Table 89. Abeona Business Overview
Table 90. Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product
Table 91. Abeona Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021) & (US$ Million)
Table 92. Abeona Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type: 2020 VS 2027
Figure 2. Glassia Features
Figure 3. Aralast NP Features
Figure 4. Prolastin C Features
Figure 5. Others Features
Figure 6. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Case Studies
Figure 8. Specialty Clinics Case Studies
Figure 9. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Report Years Considered
Figure 10. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions: 2020 VS 2027
Figure 13. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions (2022-2027)
Figure 14. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Players in 2020
Figure 15. Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in 2020
Figure 17. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Type (2016-2021)
Figure 18. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Type (2022-2027)
Figure 19. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2016-2027)
Figure 21. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2016-2027)
Figure 22. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Country (2016-2027)
Figure 23. United States Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2016-2027)
Figure 27. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2016-2027)
Figure 28. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Country (2016-2027)
Figure 29. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Region (2016-2027)
Figure 39. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2016-2027)
Figure 47. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2016-2027)
Figure 48. Latin America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Country (2016-2027)
Figure 49. Mexico Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Country (2016-2027)
Figure 55. Turkey Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Grifols Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
Figure 59. CSL Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
Figure 60. Baxter Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
Figure 61. Kamada Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
Figure 62. Takeda Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
Figure 63. Abeona Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2016-2021)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed

Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, Status and Forecast 2019-2025
QYR9NV17616 2019年11月18日 96Pages
※当調査レポートでは、α1-アンチトリプシン(AAT)欠乏症増強療法の世界市場について調査・分析し、α1-アンチトリプシン(AAT)欠乏症増強療法の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（グラ...

α1-アンチトリプシン(AAT)欠乏症増強療法のグローバル市場：規模・現状・予測2019-2025

世界の成長ホルモン欠乏療法市場規模・現状・予測（2021年-2027年）

Global Growth Hormone Deficiency Therapy Market Size, Status and Forecast 2021-2027
QFJ1-5761 2021年6月 119Pages
QYResearch社発行の本調査レポートでは、成長ホルモン欠乏療法の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（非経口、経皮、経口、その他）、用途別市場規模（病院、ドラッグストア、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本...

世界の豊胸術＆乳房形成手術市場規模・現状・予測（2021年-2027年）

Global Breast Augmentation and Reconstruction Market Size, Status and Forecast 2021-2027
QFJ1-5110 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、豊胸術＆乳房形成手術の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（豊胸手術、組織拡張器）、用途別市場規模（病院、専門クリニック）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、...

世界のCDKL5欠乏症（CDD）市場規模・現状・予測（2021年-2027年）

Global CDKL5 Deficiency Disorder (CDD) Market Size, Status and Forecast 2021-2027
QFJ1-3983 2021年6月 89Pages
QYResearch社発行の本調査レポートでは、CDKL5欠乏症（CDD）の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（従来型医薬品、新型医薬品）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中...

世界のアルギナーゼ欠損症治療薬市場規模・現状・予測（2021年-2027年）

Global Arginase Deficiency Therapeutics Market Size, Status and Forecast 2021-2027
QFJ1-3850 2021年6月 89Pages
QYResearch社発行の本調査レポートでは、アルギナーゼ欠損症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口、注射）、用途別市場規模（病院、ドラッグストア、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国...

世界のアルギナーゼ欠損症治療市場規模・現状・予測（2021年-2027年）

Global Arginase Deficiency Treatment Market Size, Status and Forecast 2021-2027
QFJ1-3851 2021年6月 88Pages
QYResearch社発行の本調査レポートでは、アルギナーゼ欠損症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口、注射）、用途別市場規模（病院、ドラッグストア、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、...

世界のオルニチン-トランスカルバミラーゼ欠損症市場規模・現状・予測（2021年-2027年）

Global Ornithine-Transcarbamylase Deficiency Market Size, Status and Forecast 2021-2027
QFJ1-4629 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、オルニチン-トランスカルバミラーゼ欠損症の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（DTX-301、SEL-313、SHP-641、PRX-OTC、その他）、用途別市場規模（病院、クリニック、その...

世界のACTH欠乏症治療市場規模・現状・予測（2021年-2027年）

Global ACTH Deficiency Treatment Market Size, Status and Forecast 2021-2027
QFJ1-3753 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、ACTH欠乏症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（先天性、後天性）、用途別市場規模（病院、薬局、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東...

世界のビオチニダーゼ欠損症市場規模・現状・予測（2021年-2027年）

Global Biotinidase Deficiency Market Size, Status and Forecast 2021-2027
QFJ1-5622 2021年6月 95Pages
QYResearch社発行の本調査レポートでは、ビオチニダーゼ欠損症の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（重度ビオチニダーゼ欠損症、部分的ビオチニダーゼ欠損症）、用途別市場規模（病院、専門クリニック、ドラッグストア、小売薬局、オンライン薬...

α1-アンチトリプシン(AAT)欠乏症増強療法のグローバル市場：規模・現状・予測2019-2025 Alpha-1 antitrypsin deficiency (AATD) is an inherited condition characterized as a low or unpredictable level of alpha-1 protein, generated by liver. The disease most commonly affects lungs and liver and is often undiagnosed. Augmentation therapy is the most specific therapy for the treatment of AAT…
α1-アンチトリプシン(AAT)欠乏症増強療法のグローバル市場：規模・現状・予測2019-2025 Alpha-1 antitrypsin deficiency (AATD) is an inherited condition characterized as a low or unpredictable level of alpha-1 protein, generated by liver. The disease most commonly affects lungs and liver and is often undiagnosed. Augmentation therapy is the most specific therapy for the treatment of AAT…
世界の成長ホルモン欠乏療法市場規模・現状・予測（2021年-2027年） Growth hormone deficiency (GHD) is a medical condition due to not enough growth hormone (GH). ... Some cases are associated with a lack of other pituitary hormones, in which case it is known as combined pituitary hormone deficiency. Diagnosis involves blood tests to measure growth hormone levels. Ma…
世界の豊胸術＆乳房形成手術市場規模・現状・予測（2021年-2027年） Breast implants are usually made up of saline or silicone and are available in either round or anatomical shape. Market Analysis and Insights: Global Breast Augmentation and Reconstruction Market The global Breast Augmentation and Reconstruction market size is projected to reach US$ XX million by 2…
世界のCDKL5欠乏症（CDD）市場規模・現状・予測（2021年-2027年） CDKL5 deficiency disorder (CDD) is a rare developmental epileptic encephalopathy (DEE), X-linked genetic condition which results in early-onset, difficult to control seizures and severe neuro-developmental impairment. CDKL5 stands for cyclin-dependent kinase-like 5 and mutations in this gene were fi…